p53 and p16(INK4A) mutations during the progression of glomus tumor

Pathology and Oncology Research

Volumn 5, Issue 1, 1999, Pages 41-45

  Güran, Şefik ^a   Tali, E Turgut ^b  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b Gazi Medical Faculty   (Turkey)

Author keywords

Glomus tumor; LOH; P53 and p16(INK4A)

Indexed keywords

DNA; PROTEIN P15; PROTEIN P16; PROTEIN P53; CARRIER PROTEIN; CDKN2B PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2B; FUNGAL PROTEIN; KIP2 PROTEIN, S CEREVISIAE; MICROSATELLITE DNA; MICROTUBULE ASSOCIATED PROTEIN; PROTEIN P16INK4A; SACCHAROMYCES CEREVISIAE PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CAROTID BODY TUMOR; CASE REPORT; CONSANGUINEOUS MARRIAGE; FAMILIAL CANCER; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; MALE; MISSENSE MUTATION; CANCER INVASION; CHEMODECTOMA; CODON; COMPARATIVE STUDY; CONSANGUINITY; DISEASE COURSE; GENETICS; MULTIPLE CANCER; MUTAGENESIS; NUCLEOTIDE SEQUENCE; PATHOLOGY; POLYMERASE CHAIN REACTION; RADIATION EXPOSURE; RADIOTHERAPY; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE; TURKEY (REPUBLIC);

ADULT; CARRIER PROTEINS; CELL CYCLE PROTEINS; CODON; CONSANGUINITY; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FUNGAL PROTEINS; GENES, P16; GENES, P53; GLOMUS JUGULARE TUMOR; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; MICROTUBULE-ASSOCIATED PROTEINS; MUTAGENESIS; MUTATION, MISSENSE; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, MULTIPLE PRIMARY; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RADIOTHERAPY; SACCHAROMYCES CEREVISIAE PROTEINS; TUMOR SUPPRESSOR PROTEINS; TURKEY;

EID: 0033084198     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1053/paor.1999.0041     Document Type: Article

References (42)

1. 1. Hirschfeld A, Kornblith P: Uncommon tumors of the nervous system. In Textbook of uncommon cancer. Eds: Williams CJ, Krikorian JG, Green MR, Raghavan D. New York John Wiley and Sons 1988, pp 590-612.
2. 2. Baysal BE, von Schonkost FM, Farr JF, et al: A high resolution STS, FST and gene based physical map of the hereditary paraganglioma region on chromosome 11q23. Genomics 44:214-221, 1997.
3. 3. Oosterwijk JC, Jansen JC, von Schothorst FM, et al: First experience with genetic counseling based on predictive DNA diagnosis in hereditary glomus tumorsparagangliomas. J Med Genet 33:379-383, 1996.
4. 4. Wang CC: Paraganglioma of the head and neck, In Textbook of uncommon cancer Eds: Williams CJ, Krikorian JG, Green MR, Raghavan D. New York, John Wiley and Sons. 1988, pp 725-729.
5. 5. Hiruta N, Kameda N, Takudome T, et al: Malignant glomus tumor: a case report and review of the literature. Am J. Surg Pathol 21:1096-1103, 1997.
6. 6. Imamura J, Miyashi I, Koeffler PH: P53 in haematologic malignancies. Blood 84:2412-2421, 1994.
7. 7. Marx J: How p53 suppress cell growth. Science 262:1644-1645, 1993.
8. 8. el-Deiry DW, Harper JW, OConnor PM, et al: WAF1/ CIP 1 is induced in p 53-mediated G1 arrest and apopitosis. Cancer Res 54:1169-1174, 1994.
9. 9. Morgan DO: Principles of CDK regulation. Nature 374:131-134, 1995.
10. 10. Nurse P: Ordering S phase and M phase in the cell cycle. Cell 79:547-550, 1994.
11. 11. Sherr CS: G1 phase progression: Cycling on clue. Cell 79:551-555, 1994.
12. 12. Hunter T and Pines J: Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell 79:573-582, 1994.
13. 13. Guan KL, Jenkins CW, Li Y, et al: Growth suppression by p18, p16(INK4/MTS1) and p14 (INK4B/MTS2)-related CDK6 inhibitor, correlates with wide-type pRb function. Genes Dev 8:2939-2952, 1994.
14. KIP2, a cyclin dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 9:639-649, 1995.
15. CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 9:650-662, 1995.
16. 16. Zhang Y, Xiong Y, Yarbrough WG: ARF promotes MDM2 degredation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725-734, 1998.
17. Arf, interacts with MDM2 and neutralizes MDM2' s inhibition of p53. Cell 92:713-725, 1998.
18. 18. Lo Coco F, Gaidano G, Louie DC, et al: P53 mutations are associated with histologic transformation of follicular lymphoma. Blood 82:2289-2295, 1993.
19. 19. Güran Ş, Bahçe M, Beyan C, et al: During the progression of Chronic Myeloid Leukemia, p53, p15, p16 and p57 mutations. Haemotologia (in press).
20. 20. Güran Ş, Pak I: Cumulation of TP53 mutations and p15p16 homozygous deletions in HPV type 16 positive scrotal cancers. Cancer Genet Cytogenet (in press).
21. 21. Tali ET, Şener RN, Ibiş E, et al: Familial bilateral glomus jugulare tumors, Neuroradiology 33:171-172, 1991.
22. 22. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning. New York. Cold Spring Harbor Lab Press 1998.
23. 23. Wright DK, Manos MM: Simple preparation from paraffin-embedded tissues. In PCR Protocols, a guide to methods and applications. Eds. Innis MA. San Diego, Academic Press Inc. pp. 153-158 1990.
24. 24. Liu L, Lassam NJ, Slingerland JM, et al: Germline p16 INK4A mutation and protein dysfunction in a family with inherited melanoma. Oncogene 11:405-412, 1995.
25. 25. Buchman VL, Chumakov PM, Ninkina NN, et al: A variation in the structure of the protein-coding region of human p53 gene. Gene 70:245-252, 1988.
26. KIP2 mutation in Beckwith-Wiedemann Syndrome. Am J Hum Genet 61:304-309, 1997.
27. 27. Orita M, Suzuki Y, Sekiya T, et al: Rapid and sensitive detection of point mutations and DNA polymorphism using the polymerase chain reaction. Genomics 5:874-879, 1989.
28. 28. Piqueras JF, Santos J, Castro IP, et al: Frequent allelic losses of 9p21 markers and low insidence of mutations at p16 (CDKN2) gene in non-Hodgkin's lymphomas of B-cell lineage. Cancer Genet Cytogenet 98:63-68, 1987.
29. 29. Weissenbach J, Gyapay G, Dib D, et al: A second-generation linkage map of the human genome. Nature 359, 798-801, 1992.
30. 30. Liu Q, Neuhausen S, Mc Clure M, et al: CDKN2 (MST1) tumor suppressor gene mutations in human cancer cell lines. Oncogene 10:1061-1067, 1995.
31. 31. Nobori T, Miura K, Wu DJ, et al: Deletions of the cyclin-dependent kinase -4 inhibitor gene in multiple human cancers. Nature 368, 753-756, 1994.
32. 32. Kwiatkowski DJ, Diaz MO: Dinucleotide repeat polymorphism at the IFNA locus (9p22). Human Mol Genet 1:658, 1992.
33. 33. Hahn M, Serth J, Fislage R, et al: Polymerase chain reaction detection of a highly polymorphic VNTR segment in intron 1 of the human p53 gene (letter). Clin Chem 39:549-550, 1993.
34. 34. Mc Daniel T, Carbone D, Takahashi T, et al: The Msp I polymorphism in intron 6 of p53 (TP53) detected by digestion of PCR products. Nucleic Acids Res 19:4796, 1991.
35. 35. Barel D, Avigad S, Mor C, et al: A novel germ-line mutation in the non-coding region of the p53 gene in a Li-Fraumeni family. Cancer Genet Cytogenet 103:1-6, 1998.
36. 36. Kiyosawa T, Umebetashi Y, Nakayama Y, et al: Hereditary multiple glomus tumors involving the gleans penis. A case report and review of the literature. Dermatol Surg 21:895-899, 1995.
37. 37. Brathwaite CD, Poppiti RS: Malignant glomus tumor. A case report of widespread metastases in a patient with multiple glomus body hamartomas. Am J Surg Pathol 20:233-238, 1996.
38. INK4A) somatic and germline mutations. Human Mutation 7:294-303, 1996.
39. 39. Alberts B, Bray D, Lewis J, et al: Cancer eds. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD in Molecular biology of the cell. New York. Garland Publishing. 1994 pp. 1255-1291.
40. 40. Gabriel FM, Sampson JH, Dodd IG, et al: Glomus jugulare tumor metastatic to the sacrum after high-dose radiation therapy: a case report. Neurosurgery 37:1001-1005, 1995.
41. 41. Levine AS, Momand S, Finlay AC: The p53 tumor suppressor gene. Nature 351:453-458, 1991.
42. 42. Lilischikis R, Sorcevic R, Kennedy C, et al: Cancer-associated missense and deletion mutations impair p16 INK4 CDK inhibitory activity. Int J Cancer 66:294-304, 1996.